drug-discovery

You can evaluate drug candidates by screening them against Lipinski Ro5, Veber rules, and CNS penetration metrics. This ADMET screening process identifies common toxicity liabilities and generates lead optimization ideas before synthesis.

The best way to retrieve bioactivity data is searching public APIs like ChEMBL to find active molecules and targets. This aggregates compound properties and early discovery data without manually checking multiple sources.

You check adverse-event signals and interaction warnings by querying the OpenFDA public API. This provides safety context and mechanism data to identify potential toxicity liabilities during drug analysis.

Yes, you can connect genes or targets to diseases using the OpenTargets public API. This maps disease associations to your compound targets to support mechanism context and open-science drug analysis.

Drug discovery analysis requires no local databases but does need public API access to ChEMBL, PubChem, OpenFDA, and OpenTargets. Rule-based evaluation of drug-likeness is performed without external software installations.

Rule-based ADMET screening is limited to evaluating Lipinski Ro5, Veber rules, and common toxicity liabilities. It provides developability estimates rather than definitive pharmacokinetic predictions for complex lead optimization scenarios.